Insider Transactions Reported by 31 Insiders of Kalaris Therapeutics, Inc.

Symbol
KLRS on Nasdaq
Location
Berkeley Heights, NJ

Insiders trading volume in the past year

Kalaris Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Srinivas Akkaraju Director, 10%+ Owner $128,667,109 +$5,000,006 +4% 22 Dec 2025
Samsara BioCapital GP, LLC 10%+ Owner $115,348,575 18 Mar 2025
Morana Jovan-Embiricos Director $21,077,598 10 Apr 2025
David Hallal Director $15,590,520 10 Apr 2025
Ansbert Gadicke Director, 10%+ Owner $11,205,689 28 Jul 2022
ElevateBio, LLC Director, 10%+ Owner $11,185,433 28 Jul 2022
GILEAD SCIENCES, INC. 10%+ Owner $11,158,950 27 Jun 2023
Vikas Sinha Officer Title: President, Chief Financial Officer and Chief Executive Officer, Director, 10%+ Owner $7,799,858 21 Feb 2025
F2 MG Ltd Director, 10%+ Owner $6,592,683 28 Jul 2022
Napoleone Ferrara Director $5,078,203 10 Apr 2025
Samir Chandrakant Patel Director $3,554,743 10 Apr 2025
John R. Wilson Director $2,123,051 25 May 2021
Juan Vera Director $1,909,386 06 Jun 2024
Diana Brainard Chief Executive Officer, Director $396,765 19 Nov 2024
Agustin Melian Chief Medical Officer $304,227 04 Oct 2021
Jeroen B. van Beek Chief Commercial Officer $223,863 16 Nov 2022
Edward Miller General Counsel $217,385 21 Feb 2025
Malcolm Brenner Director $209,111 06 Jun 2024
Cintia Piccina Chief Commercial Officer $98,608 03 Jul 2023
Ercem Atillasoy Officer $88,124 20 Oct 2022
Jeffrey S. Bornstein Director $87,309 06 Jun 2024
Ann M. Leen Chief Scientific Officer $83,183 16 Aug 2022
Shawn Tomasello Director $55,461 06 Jun 2024
Derek N. Adams Director $55,461 06 Jun 2024
Matthew Feinsod Chief Medical Officer $40,605 10 Apr 2025
Brett R. Hagen Chief Accounting Officer $17,266 -$8,135 -32% 10 Apr 2025
Matthew Gall Chief Financial Officer 03 Nov 2025
Anthony P. Adamis Director 10 Apr 2025
Andrew Oxtoby President and Chief Executive Officer, Director 10 Apr 2025
Michael Dybbs Director 10 Apr 2025
Leone D. Patterson Director 10 Apr 2025

Recent Insider Transactions by Companies or Individuals for Kalaris Therapeutics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Srinivas Akkaraju KLRS Common Stock Award 1,500,000 1,500,000 22 Dec 2025 By Samsara Opportunity Fund, L.P.
Srinivas Akkaraju KLRS Common Stock Purchase 32% $5,000,006 $10.42 479,847 1,979,847 18 Dec 2025 By Samsara Opportunity Fund, L.P.
Matthew Gall KLRS Stock Option (Right to Buy) Award 235,000 235,000 03 Nov 2025 Direct
Morana Jovan-Embiricos KLRS Stock Option (Right to Buy) Award 18,000 18,000 10 Apr 2025 Direct
Samir Chandrakant Patel KLRS Stock Option (Right to Buy) Award 18,000 18,000 10 Apr 2025 Direct
Michael Dybbs KLRS Stock Option (Right to Buy) Award 18,000 18,000 10 Apr 2025 Direct
Brett R. Hagen KLRS Stock Option (Right to Buy) Award 50,262 50,262 10 Apr 2025 Direct
Srinivas Akkaraju KLRS Stock Option (Right to Buy) Award 18,000 18,000 10 Apr 2025 Direct
Napoleone Ferrara KLRS Stock Option (Right to Buy) Award 18,000 18,000 10 Apr 2025 Direct
Andrew Oxtoby KLRS Stock Option (Right to Buy) Award 287,000 287,000 10 Apr 2025 Direct
Anthony P. Adamis KLRS Stock Option (Right to Buy) Award 18,000 18,000 10 Apr 2025 Direct
Matthew Feinsod KLRS Stock Option (Right to Buy) Award 171,551 101,000 10 Apr 2025 Direct
Leone D. Patterson KLRS Stock Option (Right to Buy) Award 18,000 18,000 10 Apr 2025 Direct
David Hallal KLRS Stock Option (Right to Buy) Award 18,000 18,000 10 Apr 2025 Direct
Brett R. Hagen KLRS Common Stock Sale -32% $8,135 $8.97 -907 1,925 26 Mar 2025 Direct
Napoleone Ferrara KLRS Common Stock Award 504,000 504,000 18 Mar 2025 Direct
Samir Chandrakant Patel KLRS Common Stock Award 100,800 100,800 18 Mar 2025 See footnote
Samir Chandrakant Patel KLRS Common Stock Award 252,000 252,000 18 Mar 2025 Direct
Samir Chandrakant Patel KLRS Stock Option (right to buy) Award 105,913 105,913 18 Mar 2025 Direct
Matthew Feinsod KLRS Common Stock Award 4,030 4,030 18 Mar 2025 Direct
Matthew Feinsod KLRS Stock Option (right to buy) Award 28,224 28,224 18 Mar 2025 Direct
Andrew Oxtoby KLRS Stock Option (right to buy) Award 476,611 476,611 18 Mar 2025 Direct
Srinivas Akkaraju KLRS Common Stock Award 11,444,503 11,444,503 18 Mar 2025 See footnote
Anthony P. Adamis KLRS Stock Option (right to buy) Award 32,473 19,484 18 Mar 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.